| Generic Name |
Bevacizumab-awwb |
| Brand Name |
Mvasi |
| Payment Category |
Medicare Part B |
| Year Introduced |
2017 |
| Type of Drug |
Biosimilar vascular endothelial growth factor-specific angiogenesis inhibitor |
| Manufacturer |
Amgen |
| Medical Affairs Questions (date verified) |
800.772.6436 |
| Coverage & Reimbursement Questions |
855.669.9360 |
| HCPCS |
Q5107 |
| Billing Unit |
10 mg |
| Medicare Payment Limit (Effective January 1, 2021) |
$56.73 |
FDA-Approved Indication(s)
- Indicated for 1) Metastatic colorectal cancer, with a) intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment, or b) fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen; 2) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease; 3) Recurrent glioblastoma in adults as a single agent; 4) Metastatic renal cell carcinoma with interferon alfa; and 5) Cervical cancer, in combination with paclitaxel and cisplatin or topotecan in persistent, recurrent, or metastatic disease. (6/25/19)
|
| ICD-10 Code(s) for Labeled Indication(s) |
Colorectal cancers [C18.x, C19, C20,or C21.x, dependent on location]; Malignant neoplasm of bronchus and lung [C34.xx]; Malignant neoplasm of brain [C71.x]; Malignant neoplasm of kidney [C64.x] or renal pelvis [C65.x]; Malignant neoplasm of cervix uteri _[C53.x] |
